Skip to Main Content

Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

Conditions

Diseases of the Cardiovascular System

What is the purpose of this trial?

The purpose of the study is to collect information on patients who have been diagnosed with transthyretin-associated amyloidosis who carry a mutation in the gene that could lead to this disease.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Start Date
    06/03/2014
  • End Date
    06/29/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/06/2020
  • Study HIC
    #1306012239